Crossmark

Pervasive supply of therapeutic lysosomal enzymes in the CNS of normal and Krabbe‐affected non‐human primates by intracerebral lentiviral gene therapy

Crossref DOI link: https://doi.org/10.15252/emmm.201505850

Published Online: 2016-03-29

Published Print: 2016-05-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Meneghini, Vasco

Lattanzi, Annalisa

Tiradani, Luigi

Bravo, Gabriele

Morena, Francesco

Sanvito, Francesca

Calabria, Andrea

Bringas, John

Fisher‐Perkins, Jeanne M

Dufour, Jason P

Baker, Kate C

Doglioni, Claudio

Montini, Eugenio

Bunnell, Bruce A

Bankiewicz, Krystof

Martino, Sabata

Naldini, Luigi

Gritti, Angela
Funding

Funding for this research was provided by:

Fondazione Telethon (TGT11B02)

NIH (OD 11104)

TNRPC
License Information

Text and Data Mining valid from 2016-03-29

Version of Record valid from 2016-03-29
More Information

Article History

Received: 11 September 2015

Revised: 22 February 2016

Accepted: 1 March 2016

First Online: 29 March 2016

Conflict of interest

: LN is an inventor on pending and issued patents on lentiviral vector technology filed by the Salk Institute, Cell Genesys, Telethon Foundation and/or San Raffaele Scientific Institute. The other authors declare that they have no conflict of interest.

Document is current

Any future updates will be listed below